Morning versus afternoon infusions for advanced bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether getting your bladder cancer infusion at a specific time of day (morning vs. afternoon) affects how well the treatment works. You'll receive the standard drugs enfortumab vedotin and pembrolizumab, but your infusion time will be randomly assigned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced bladder cancer that started in the lining of the bladder (urothelial cancer).
- Your doctor has told you that you can receive the standard combination treatment of enfortumab vedotin and pembrolizumab (EV/P).
- You are able to commit to getting your infusion either before 11:30 a.m. or after 1:30 p.m. for the first 3 months.
- You do not work night shifts, have recently traveled across multiple time zones, or have an untreated sleep disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) given before surgery to shrink or eliminate bladder or upper tract cancer. The goal is to see if this approach reduces the chance of cancer coming back and improves outcomes.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Hear when a new Advanced Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.